Current status of CD44 variant isoforms as cancer diagnostic markers

Histopathology

Volumn 32, Issue 1, 1998, Pages 1-6

  Goodison, S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cancer diagnosis; CD44; Neoplasia

Indexed keywords

CELL SURFACE PROTEIN; DNA; EPITOPE; HERMES ANTIGEN; MESSENGER RNA; MONOCLONAL ANTIBODY;

ARTICLE; CANCER DIAGNOSIS; CELL ADHESION; GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSLATION; SOUTHERN BLOTTING;

ANTIGENS, CD44; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VARIATION (GENETICS);

EID: 0031936838     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1998.00262.x     Document Type: Article

References (3)

1. Goodfellow PN, Banting G, Wiles MV et al. The gene. MIC4. which controls expression of the antigen defined by monoclonal antibody F10.44.2. is on human chromosome 11. Eur. J. Immunol. 1982 12: 659-663.
2. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced cxons. Proc. Natl. Acad. Sci. USA 1992 89: 121 60-121 64.
3. Tolg C, Hofmann M, Herrlich P, Ponta H. Splicing choice from ten variant exons establishes CD44 variability. Nuc. Acids Res. 1993 21: 1225-1229.